Clinical Trial

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Study acronym: LAG-BOOST
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-29.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07223541
Lead Sponsor University of Oklahoma
Collaborators: Regeneron Pharmaceuticals
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 72 participants
Start Date 2026-01-15
Primary Completion 2029-08 (estimated)
Study Completion 2031-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-02